Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Erythropoietin Induced Hypertension
NCT03810911Phase 2Terminated
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darbepoetin alfa in anemia (2 arms), sponsored by VA Office of Research & Development. Primary endpoints: Change in Diastolic Blood Pressure at 12 weeks and Within Group Change in Diastolic Blood Pressure in the Delayed Start Group at 24 weeks. Started Jan 2021; status: terminated.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03810911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810911.